Oral delivery of pentameric glucagon-like peptide-1 by recombinant lactobacillus in diabetic rats

PLoS ONE

Volumn 11, Issue 9, 2016, Pages

  Lin, Yin ^a   Krogh Andersen, Kasper ^a   Pelletier, Julien ^a   Marcotte, Harold ^a   Östenson, Claes Göran ^a   Hammarström, Lennart ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE; TRYPSIN; GLUCOSE BLOOD LEVEL; INSULIN; PEPTIDE LIBRARY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG DELIVERY SYSTEM; ESCHERICHIA COLI; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; GLYCEMIC CONTROL; IN VITRO STUDY; IN VIVO STUDY; INSULIN RELEASE; LACTOBACILLUS PARACASEI; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT; ANIMAL; BLOOD; BODY WEIGHT; CELL LINE; DIABETES MELLITUS, EXPERIMENTAL; DRUG EFFECTS; FEEDING BEHAVIOR; GENETIC RECOMBINATION; GENETIC TRANSFORMATION; GENETICS; LACTOBACILLUS; MESOCRICETUS; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOLOGY; PEPTIDE LIBRARY; REPRODUCIBILITY; SECRETION (PROCESS); SUBCUTANEOUS DRUG ADMINISTRATION; WESTERN BLOTTING;

ADMINISTRATION, ORAL; ANIMALS; BLOOD GLUCOSE; BLOTTING, WESTERN; BODY WEIGHT; CELL LINE; DIABETES MELLITUS, EXPERIMENTAL; DRUG DELIVERY SYSTEMS; ESCHERICHIA COLI; FEEDING BEHAVIOR; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; INJECTIONS, SUBCUTANEOUS; INSULIN; LACTOBACILLUS; MALE; MESOCRICETUS; PEPTIDE LIBRARY; RATS; RECOMBINATION, GENETIC; REPRODUCIBILITY OF RESULTS; TRANSFORMATION, GENETIC; TRYPSIN;

EID: 84991011421     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0162733     Document Type: Article

References (50)

1. Kumar V, Abbas AK, Fausto N, Robbins SL, Cotran RS. Robbins and Cotran pathologic basis of disease. Philadelphia: Elsevier Saunders; 2005.
2. Nauck MA. Is glucagon-like peptide 1 an incretin hormone'Diabetologia. 1999; 42(3):373-9. doi: 10. 1007/s001250051165 PMID: 10096792.
3. Shirazi R, Palsdottir V, Collander J, Anesten F, Vogel H, Langlet F, et al. Glucagon-like peptide 1 receptor induced suppression of food intake, and body weight is mediated by central IL-1 and IL-6. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110(40):16199-204. doi: 10.1073/pnas.1306799110 PMID: 24048027; PubMed Central PMCID: PMC3791711.
4. Holst JJ. The physiology of glucagon-like peptide 1. Physiological reviews. 2007; 87(4):1409-39. Epub 2007/10/12. doi: 10.1152/physrev.00034.2006 PMID: 17928588.
5. Arulmozhi DK, Portha B. GLP-1 based therapy for type 2 diabetes. European journal of pharmaceutical sciences: official journal of the European Federation for Pharmaceutical Sciences. 2006; 28(1-2): 96-108. doi: 10.1016/j.ejps.2006.01.003 PMID: 16488579.
6. Levy JC. Therapeutic intervention in the GLP-1 pathway in Type 2 diabetes. Diabetic Medicine. 2006; 23:14-9. doi: 10.1111/j.1464-5491.2006.01833e.x PMID: 16483260
7. ChiaCW, Egan JM. Incretin-based therapies in type 2 diabetes mellitus. The Journal of clinical endocrinology and metabolism. 2008; 93(10):3703-16. doi: 10.1210/jc.2007-2109 PMID: 18628530; PubMed Central PMCID: PMC2579648.
8. Fehmann HC, Göke B. The Insulinotropic Gut HormoneGlucagon-like Peptide-1: Karger; 1997.
9. Hui H, Farilla L, Merkel P, Perfetti R. The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects. European journal of endocrinology/European Federation of Endocrine Societies. 2002; 146(6):863-9. PMID: 12039708.
10. Bond A. Exenatide (Byetta) as a novel treatment option for type 2 diabetes mellitus. Proceedings. 2006; 19(3):281-4. PMID: 17252050; PubMed Central PMCID: PMC1484540.
11. Garber AJ. Long-Acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes care. 2011; 34 Suppl 2:S279-84. doi: 10.2337/dc11-s231 PMID: 21525469; PubMed Central PMCID: PMC3632193.
12. Burcelin R, DolciW, Thorens B. Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1. Metabolism: clinical and experimental. 1999; 48(2):252-8. Epub 1999/02/19. PMID: 10024091.
13. SteinertRE, Poller B, CastelliMC, Friedman K, Huber AR, Drewe J, et al. Orally Administered Glucagon-Like Peptide-1 Affects Glucose Homeostasis Following an Oral Glucose Tolerance Test in Healthy Male Subjects. Clinical Pharmacology & Therapeutics. 2009; 86(6):644-50. doi: 10.1038/clpt.2009.159
14. Araujo F, Fonte P, Santos HA, Sarmento B. Oral delivery of glucagon-like peptide-1 and analogs: alternatives for diabetes control' Journal of diabetes science and technology. 2012; 6(6):1486-97. Epub 2013/01/09. PMID: 23294796; PubMed Central PMCID:PMCPMC3570891.
15. Youn YS, Chae SY, Lee S, Kwon MJ, Shin HJ, Lee KC. Improved peroral delivery of glucagon-like peptide-1 by site-specific biotin modification: design, preparation, and biological evaluation. European journal of pharmaceutics and biopharmaceutics: official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV. 2008; 68(3):667-75. doi: 10.1016/j.ejpb.2007.07.009 PMID: 17904340.
16. Chae SY, Jin CH, Shin HJ, Youn YS, Lee S, Lee KC. Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery. Bioconjugate chemistry. 2008; 19(1):334-41. doi: 10.1021/bc700292v PMID: 18078308.
17. Joseph JW, Kalitsky J, St-PierreS, Brubaker PL. Oral delivery of glucagon-like peptide-1 in a modified polymer preparation normalizes basal glycaemia in diabetic db/db mice. Diabetologia. 2000; 43(10): 1319-28. doi: 10.1007/s001250051529 PMID: 11079752.
18. Nguyen HN,Wey SP, Juang JH, Sonaje K, Ho YC, Chuang EY, et al. The glucose-lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticlevehicle and effects on subsequent insulin secretion in vivo. Biomaterials. 2011; 32(10):2673-82. doi: 10.1016/j.biomaterials.2010.12.044 PMID: 21256586.
19. Wells JM, Mercenier A. Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nature reviews Microbiology. 2008; 6(5):349-62. doi: 10.1038/nrmicro1840PMID: 18345021.
20. Tabuchi M, Ozaki M, Tamura A, Yamada N, Ishida T, Hosoda M, et al. Antidiabetic effect of Lactobacillus GG in streptozotocin-induced diabetic rats. Bioscience, biotechnology, and biochemistry. 2003; 67(6):1421-4. doi: 10.1271/bbb.67.1421 PMID: 12843677.
21. Yun SI, Park HO, Kang JH. Effect of Lactobacillus gasseri BNR17 on blood glucose levels and body weight in a mouse model of type 2 diabetes. Journal of applied microbiology. 2009; 107(5):1681-6. doi: 10.1111/j.1365-2672.2009.04350.x PMID: 19457033.
22. Duan FF, Liu JH, March JC. Engineered commensal bacteria reprogramintestinal cells into glucoseresponsive insulin-secreting cells for the treatment of diabetes. Diabetes. 2015; 64(5):1794-803. Epub 2015/01/30. doi: 10.2337/db14-0635 PMID: 25626737; PubMed Central PMCID:PMCPMC4407861.
23. Gunaydin G, Alvarez B, Lin Y, Hammarstrom L, Marcotte H. Co-expression of anti-rotavirus proteins (llama VHH antibody fragments) in Lactobacillus: development and functionality of vectors containing two expression cassettes in tandem. PloS one. 2014; 9(4):e96409. doi: 10.1371/journal.pone.0096409 PMID: 24781086; PubMed Central PMCID: PMC4004553.
24. Andersen KK, Marcotte H, Alvarez B, Boyaka PN, Hammarstrom L. In situ gastrointestinal protection against anthrax edema toxin by single-chain antibody fragment producing lactobacilli. BMC Biotechnol. 2011; 11:126. Epub 2011/12/22. doi: 10.1186/1472-6750-11-126 PMID: 22185669; PubMed Central PMCID:PMCPMC3295704.
25. Maze A, Boel G, Zuniga M, Bourand A, Loux V, Yebra MJ, et al. Complete genome sequence of the probiotic Lactobacillus casei strain BL23. Journal of bacteriology. 2010; 192(10):2647-8. doi: 10.1128/JB. 00076-10 PMID: 20348264; PubMed Central PMCID: PMC2863562.
26. Acedo-Felix E, Perez-Martinez G. Significant differences between Lactobacillus casei subsp. casei ATCC 393T and a commonly used plasmid-cured derivative revealed by a polyphasic study. International journal of systematic and evolutionary microbiology. 2003; 53(Pt 1):67-75. Epub 2003/03/27. doi: 10.1099/ijs.0.02325-0 PMID: 12656154.
27. MartinMC, Pant N, Ladero V, Gunaydin G, Andersen KK, Alvarez B, et al. Integrative expression system for delivery of antibody fragments by lactobacilli. Applied and environmental microbiology. 2011; 77(6):2174-9. doi: 10.1128/AEM.02690-10 PMID: 21257814; PubMed Central PMCID: PMC3067310.
28. KrugerC, Hu Y, Pan Q, Marcotte H, Hultberg A, Delwar D, et al. In situ delivery of passive immunity by lactobacilli producing single-chain antibodies. Nature biotechnology. 2002; 20(7):702-6. doi: 10.1038/nbt0702-702 PMID: 12089555.
29. Marcotte H, Koll-Klais P, Hultberg A, Zhao Y, Gmur R, Mandar R, et al. Expression of single-chain antibody against RgpA protease of Porphyromonas gingivalis in Lactobacillus. Journal of applied microbiology. 2006; 100(2):256-63. doi: 10.1111/j.1365-2672.2005.02786.x PMID: 16430501.
30. Santerre RF, Cook RA, Crisel RM, Sharp JD, Schmidt RJ, WilliamsDC, et al. Insulin synthesis in a clonal cell line of simian virus 40-transformed hamster pancreatic beta cells. Proceedings of the National Academy of Sciences of the United States of America. 1981; 78(7):4339-43. PMID: 6270673; PubMed Central PMCID: PMC319785.
31. Ostenson CG, Efendic S. Islet gene expression and function in type 2 diabetes; studies in the Goto-Kakizaki rat and humans. Diabetes, obesity & metabolism. 2007; 9 Suppl 2:180-6. doi: 10.1111/j.1463-1326.2007.00787.x PMID: 17919192.
32. Ostenson CG, Grill V. Differences in long-termeffects of L-glutamine and D-glucose on insulin release from rat pancreatic islets. Molecular and cellular endocrinology. 1986; 45(2-3):215-21. PMID: 3086158.
33. HerbertV, Lau KS, GottliebCW, Bleicher SJ. Coated charcoal immunoassay of insulin. The Journal of clinical endocrinology and metabolism. 1965; 25(10):1375-84. doi: 10.1210/jcem-25-10-1375 PMID: 5320561.
34. Yassin K, Huyen VT, Hoa KN, Ostenson CG. Herbal extract of gynostemma pentaphyllum decreases hepatic glucose output in type 2 diabetic goto-kakizaki rats. International journal of biomedical science: IJBS. 2011; 7(2):131-6.Epub 2011/06/01. PMID: 23675229; PubMed Central PMCID: PMCPMC3614830.
35. MullerC, Yassin K, Li LS, Palmblad M, Efendic S, BerggrenPO, et al. ARA290 improves insulin release and glucose tolerance in type 2 diabetic GK rats. Molecular medicine (Cambridge, Mass). 2015. Epub 2016/01/07. doi: 10.2119/molmed.2015.00267 PMID: 26736179; PubMed Central PMCID: PMCPMC4818260.
36. Chaikomin R, Doran S, Jones KL, Feinle-Bisset C, O'Donovan D, Rayner CK, et al. Initially more rapid small intestinal glucose delivery increases plasma insulin, GIP, and GLP-1 but does not improve overall glycemia in healthy subjects. American journal of physiology Endocrinology and metabolism. 2005; 289(3):E504-7. Epub 2005/05/12. doi: 10.1152/ajpendo.00099.2005 PMID: 15886226.
37. Kuo P, Chaikomin R, Pilichiewicz A, O'Donovan D, Wishart JM, Meyer JH, et al. Transient, early release of glucagon-like peptide-1 during low rates of intraduodenal glucose delivery. Regulatory peptides. 2008; 146(1-3):1-3. Epub 2007/10/30. doi: 10.1016/j.regpep.2007.09.032 PMID: 17964673.
38. Suzuki S, Kawai K, Ohashi S, Mukai H, Yamashita K. Comparison of the effects of various C-terminal and N-terminal fragment peptides of glucagon-like peptide-1 on insulin and glucagon release from the isolated perfused rat pancreas. Endocrinology. 1989; 125(6):3109-14. Epub 1989/12/01. doi: 10.1210/endo-125-6-3109 PMID: 2684616.
39. Donnelly D. The structure and function of the glucagon-like peptide-1 receptor and its ligands. British journal of pharmacology. 2012; 166(1):27-41. doi: 10.1111/j.1476-5381.2011.01687.x PMID: 21950636; PubMed Central PMCID: PMC3415635.
40. Petersen TN, Brunak S, von Heijne G, Nielsen H. SignalP 4.0: discriminating signal peptides from transmembrane regions. Nature methods. 2011; 8(10):785-6. doi: 10.1038/nmeth.1701 PMID: 21959131.
41. Mathiesen G, Sveen A, BrurbergMB, Fredriksen L, Axelsson L, Eijsink VG. Genome-wide analysis of signal peptide functionality in Lactobacillus plantarum WCFS1.BMC genomics. 2009; 10:425. doi: 10. 1186/1471-2164-10-425 PMID: 19744343; PubMed Central PMCID: PMC2748100.
42. Akash MS, Rehman K, Chen S. Goto-Kakizaki rats: its suitability as non-obese diabetic animal model for spontaneous type 2 diabetes mellitus. Current diabetes reviews. 2013; 9(5):387-96. PMID: 23855509.
43. Agarwal P, Khatri P, Billack B, Low WK, Shao J. Oral delivery of glucagon like peptide-1 by a recombinant Lactococcus lactis. Pharmaceutical research. 2014; 31(12):3404-14. doi: 10.1007/s11095-014-1430-3 PMID: 24928365.
44. Steidler L, Neirynck S, Huyghebaert N, Snoeck V, Vermeire A, Goddeeris B, et al. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin Nature biotechnology. 2003; 21(7):785-9. doi: 10.1038/nbt840 PMID: 12808464.
45. Steidler L, HansW, Schotte L, Neirynck S, ObermeierF, Falk W, et al. Treatment ofmurine colitis by Lactococcus lactis secreting interleukin-10. Science. 2000; 289(5483):1352-5. PMID: 10958782.
46. Naito E, Yoshida Y, Makino K, Kounoshi Y, Kunihiro S, Takahashi R, et al. Beneficial effect of oral administration of Lactobacillus casei strain Shirota on insulin resistance in diet-induced obesity mice. Journal of applied microbiology. 2011; 110(3):650-7. doi: 10.1111/j.1365-2672.2010.04922.x PMID: 21281408.
47. Hsieh FC, Lee CL, Chai CY, Chen WT, Lu YC,Wu CS. Oral administration of Lactobacillus reuteri GMNL-263 improves insulin resistance and ameliorates hepatic steatosis in high fructose-fed rats. Nutrition& metabolism. 2013; 10(1):35. doi: 10.1186/1743-7075-10-35PMID: 23590862; PubMed Central PMCID: PMC3637306.
48. Lin CH, Lin CC, Shibu MA, Liu CS, Kuo CH, Tsai FJ, et al. Oral Lactobacillus reuteriGMN-32 treatment reduces blood glucose concentrations and promotes cardiac function in rats with streptozotocininduced diabetes mellitus. The British journal of nutrition. 2014; 111(4):598-605. doi: 10.1017/S0007114513002791 PMID: 24001238.
49. SimonMC, Strassburger K, Nowotny B, Kolb H, Nowotny P, BurkartV, et al. Intake of Lactobacillus reuteri Improves Incretin and Insulin Secretion in Glucose-Tolerant Humans: A Proof of Concept. Diabetes care. 2015; 38(10):1827-34. Epub 2015/06/19. doi: 10.2337/dc14-2690 PMID: 26084343.
50. Panwar H, Rashmi HM, Batish VK, Grover S. Probiotics as potential biotherapeutics in the management of type 2 diabetes-prospects and perspectives. Diabetes/metabolism research and reviews. 2013; 29(2):103-12. Epub 2012/12/12. doi: 10.1002/dmrr.2376 PMID: 23225499.